CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand; Mikael Oscarson; Jarmo S. Salonen; Leena Nyman; Olavi Pelkonen; Miia Turpeinen; Magnus Ingelman-Sundberg

Research ArticleArticle

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg

Drug Metabolism and Disposition November 2001, 29 (11) 1480-1484;

Mats Hidestrand

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mikael Oscarson

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jarmo S. Salonen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Leena Nyman

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Olavi Pelkonen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Miia Turpeinen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Magnus Ingelman-Sundberg

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF

DMD articles become freely available 12 months after publication, and remain freely available for 5 years.

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.

Click here for information on institutional subscriptions.
Click here for information on individual ASPET membership.

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

PreviousNext

In this issue

Drug Metabolism and Disposition

Vol. 29, Issue 11

1 Nov 2001

Table of Contents
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Message Subject (Your Name) has forwarded a page to you from Drug Metabolism & Disposition

Message Body (Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleArticle

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg

Drug Metabolism and Disposition November 1, 2001, 29 (11) 1480-1484;

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Research ArticleArticle

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg

Drug Metabolism and Disposition November 1, 2001, 29 (11) 1480-1484;

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
eLetters
PDF

Main menu

User menu

Search

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

DMD articles become freely available 12 months after publication, and remain freely available for 5 years.

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.

Purchase access

In this issue

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Navigate

More Information

ASPET's Other Journals